Hemophilia is a rare congenital disorder which impairs the ability of the blood to clot properly. This disorder is characterized by the bleeding into the joints which leads to swelling and pain or tightness in the joints. It also causes bleeding into the skin which results in building up of blood in hematoma. Studies have reflected that hemophilia is found to be more common in males in contrast to females. Hemophilia is caused due to the genetic mutation in the DNA sequence of the genes responsible for major role in the blood clotting process. Based on the deficiency of coagulating factor hemophilia is classified into three different types viz. Hemophilia A, Hemophilia B and Hemophilia C. Coming to its occurrence, high incidence rate is observed in EU 5 Market (United Kingdom, France, Germany, Spain and Italy) as compared to United States and Japan. If we talk about the types then; Hemophilia A is more prevalent as compared to Hemophilia B.
It is forecasted that Hemophilia therapeutics market in seven major markets is expected to increase to USD 13,751.6 million by the end of 2023. United States has the largest market share whereas Spain contributes the lowest market share in 2016. Hemophilia A contributes the major share of the market as compared to Hemophilia B. Several factors such as the development of novel coagulating factors, technological advancement, and advancement in diagnosis techniques are stimulating the growth of the market.
If we see the Market Scenario then the market is dominated with several recombinant proteins developed by the major players such as Baxter, Bayer, and Pfizer. BeneFIX developed by Pfizer is leading the race for Hemophilia B whereas Advate developed by Baxalta (Now Shire) is leading the race for Hemophilia A.
Approval of Idelvion developed by CSLBehring for Hemophilia B and Kovaltry developed by Bayer for Hemophilia A in March 2016 by USFDA will play a major role in stimulating the growth of the market. Also, the lost of patents of Kogenate and Novoseven in 2014 and 2010 respectively will impact the market growth.
The pipeline of Hemophilia is robust with the involvement of novel therapies being developed by major players such as Hoffmann-La Roche, Novo Nordisk, Pfizer and Shire plc. Companies such as Biogen and Baxalta have entered into collaborations for bringing the gene therapy for Hemophilia in future. The launch of emerging therapies such as Refixia for Hemophilia B, Turoctocog alfa pegol for Hemophilia A , LR769 for Hemophilia A and Hemophilia B , Emicizumab and Damoctocog alfa pegol for Hemophilia A will further fuel the market growth. Launch of the Adynovate in Europe in 2018 for Hemophilia A which is already approved in United States and Japan as an on-demand treatment for Hemophilia will have the major impact in market.